A secondary analysis of a 6-month randomized trial found that higher baseline weight-loss self-efficacy predicted at least 5% weight loss in both diet arms, with BMI and age as arm-specific predictors. PICO summary and expert commentary.
Browsing: Metabolism
Obesity and weight management, metabolic syndrome and insulin resistance, MASLD/fatty liver, and nutrition and lifestyle evidence.
A secondary lipidomic analysis of two randomized crossover feeding trials found that lowering dietary saturated fat reshaped the lipoprotein(a) lipidome while plasma Lp(a) rose. PICO summary and expert commentary.
A 12-week randomised trial in older adults with type 2 diabetes testing whether combined aerobic plus resistance exercise improves sleep and abdominal fat. PICO summary and expert commentary.
An exploratory analysis within the FLIPAN trial links larger liver-fat reductions on a Mediterranean diet to mixed environmental signals, with only higher water use surviving adjustment. PICO summary and expert commentary.
A healthy-volunteer pharmacokinetic crossover trial found magnesium aspartate reduced levothyroxine absorption by 12 percent, while magnesium citrate had a smaller, non-significant effect. PICO summary and expert commentary.
A 7-week double-blind RCT found aripiprazole caused significantly less weight gain than risperidone in schizophrenia, with appetite changes as an early metabolic signal. PICO summary and expert commentary.
A 93-patient Turkish RCT testing whether more frequent dietitian counseling, with weekly telehealth added, improves cardiometabolic outcomes in metabolic syndrome. PICO summary and expert commentary.
A three-arm RCT shows 24 g/day dietary fibre improves HbA1c and the FIB-4 fibrosis marker in type 2 diabetes with MASLD. PICO summary and expert commentary for clinicians.
The DPPOS demonstrated that cumulative diabetes prevention from the DPP lifestyle intervention and metformin persists over 10 years from original randomisation, with 34% and 18% reductions in cumulative diabetes incidence despite post-DPP convergence of care, establishing a diabetes prevention legacy effect and confirming the durability of early preventive intervention.
The DREAM trial demonstrated that rosiglitazone reduces incident diabetes or death by 60% and achieves normoglycaemia in 50% of high-risk adults with impaired glucose tolerance, the largest pharmacological diabetes prevention effect documented in a large RCT, but the drug’s subsequent cardiovascular safety concerns and market withdrawal have prevented translation of these findings into clinical practice.